Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is designed to bring together factor IXa and factor X, proteins required to activate the natural coagulation cascade and restore the blood clotting process for people with haemophilia A. Hemlibra is a prophylactic (preventative) treatment that can be administered by an injection of a ready-to-use solution under the skin (subcutaneously) once-weekly, every two weeks or every four weeks.
Hemlibra is approved in over 50 countries worldwide, including the US, EU member states and Japan, to treat people of all ages with haemophilia A with factor VIII inhibitors. In October 2018, the U.S. FDA also approved Hemlibra to treat people of all ages with haemophilia A without factor VIII inhibitors.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions.